Journal
CLINICAL INFECTIOUS DISEASES
Volume 75, Issue 2, Pages 334-337Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab1026
Keywords
small molecule kinase inhibitors; ibrutinib; invasive fungal infections; cancer; opportunistic infections
Categories
Ask authors/readers for more resources
We examined the incidence of invasive fungal infections (IFIs) within the first year of small molecule kinase inhibitor (SMKI) therapy based on administrative data analysis. The occurrence of IFIs ranged from 0.0% to 10.6% depending on the specific SMKI used, with midostaurin showing the highest incidence. Among the 1286 patients treated with ibrutinib, 38 individuals (3.0%) developed IFIs.
We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available